Literature DB >> 1315673

[Angioneurotic edema caused by angiotensin-converting enzyme inhibitors].

K L Diehl1, H Wernze.   

Abstract

Inhibition of angiotensin converting enzyme (ACE) may cause angioneurotic oedema. In order to define the clinical spectrum of this important adverse effect, we analysed data on 60 patients with angioneurotic oedema notified to the Drug Commission of the German Medical Association, after taking captopril (n = 24), enalapril (n = 25) or lisinopril (n = 11). In 48 cases the oedema affected the face, tongue and pharynx, while swelling of the extremities (n = 4), the trunk (n = 2) or the genitalia (n = 1) was observed less frequently. While oedema appeared most often after 1 to 21 days, it started within an hour in one patient, and only after 6 months of therapy in five patients. After discontinuation of the ACE inhibitor, the angioneurotic oedema resolved within 72 hours; additional therapeutic measures (glucocorticoids, antihistamines, adrenaline, C1 inhibitors) did not shorten the recovery time. In view of the increasing use of ACE inhibitors, the features of this unusual adverse reaction need to be widely recognized, since angioneurotic oedema of the larynx is potentially life-threatening.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315673     DOI: 10.1055/s-2008-1062369

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

1.  Angioedema due to ACE inhibitors: increased risk in patients of African origin.

Authors:  C R Gibbs; G Y Lip; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  [Chronic hyperplastic laryngitis following treatment of hypertension with angiotensin converting enzyme-inhibitor].

Authors:  M Fuchs; M Bücheler
Journal:  HNO       Date:  2004-11       Impact factor: 1.284

Review 3.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

4.  Chronic urticaria and use of statins.

Authors:  Sujoy Khan
Journal:  Asia Pac Allergy       Date:  2012-07-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.